Surgical treatment of hepatic colorectal metastasis: Evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century

Cancer Journal

Volumn 16, Issue 2, 2010, Pages 103-110

  Ito, Kaori ^a,b   Govindarajan, Anand ^b   Ito, Hiromichi ^a,b   Fong, Yuman ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; Cryoablation; Microwave ablation; Neoadjuvant; Radiofrequency ablation; Recurrence pattern; Surgical outcome

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ALGORITHM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL SYNCHRONIZATION; COLON RESECTION; COLORECTAL CANCER; COST; CRYOABLATION; DISEASE FREE INTERVAL; FOLLOW UP; HEPATIC COLORECTAL METASTASIS; HOSPITALIZATION; HUMAN; LIFE EXTENSION; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; MICROWAVE RADIATION; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL TIME; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; CATHETER ABLATION; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; TIME FACTORS;

EID: 77951434955     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181d7e8e5     Document Type: Review

References (77)

1. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
2. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
3. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
4. Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg. 1987;11:541-547.
5. Bozzetti F, Bignami P, Morabito A, et al. Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg. 1987;205: 264-270.
6. Picardo A, Karpoff H, Ng B, et al. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery. 1998;124: 57-64.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
8. Saltz LB, Clarke S, Az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
9. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-447.
10. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surgical Oncol. 2001;8:347-353.
11. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10 Suppl):S22-S31.
12. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235:759-766.
13. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487-499.
14. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505-511.
15. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery. 1994;116:703-711.
16. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100:278-284.
17. Fortner JG, Fong Y. Twenty-five year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner. Ann Surg. 2009;250:908-913.
18. Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high volume centers. Ann Surg. 2005;242:540-547.
19. Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection for malignancy is safe and effective in the elderly. Ann Surg. 1995;222:426-437.
20. Weber SM, Jarnagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000;7:643-650.
21. Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am. 1989;69:339-359.
22. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 1993;71(S12):4252-4266.
23. Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13-29.
24. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992;216:492-505.
25. Stephenson KR, Steinberg SM, Hughes KS, et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg. 1988;208: 679-687.
26. Mala T, Bohler G, Mathisen O, et al. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26:1348-1353.
27. Chen YY, Perera DS, Yan TD, et al. Applying Fong's CRS score in patients with colorectal liver metastases treated by cryotherapy. Asian J Surg. 2006; 29:238-241.
28. Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, et al. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg. 2004;8:150-157.
29. Jarnagin WR, Conlon K, Bodniewicz J, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer. 2001;91:1121-1128.
30. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743-751.
31. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003; 197:233-241.
32. Reddy S, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multiinstitutional analysis. Ann Surg Oncol. In press.
33. Martin RC, Augenstein V, Reuter NP, et al. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009;208:842-850.
34. Mala T. Cryoablation of liver tumours-a review of mechanisms, techniques and clinical outcome. Minim Invasive Ther Allied Technol. 2006;15:9-17.
35. Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol. 2004;5:550-560.
36. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2009;17:171-178.
37. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493-508.
38. Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-451.
39. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
40. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15:2757-2764.
41. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003;10:338-347.
42. Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007; 246:559-565.
43. Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12:1967-1972.
44. Maeda T, Hasebe Y, Hanawa S, et al. Trial of percutaneous hepatic cryotherapy: preliminary report. Nippon Geka Gakkai Zasshi-J Japn Surg Soc. 1992;93:666.
45. Hohenberger P, Schlag P, Schwarz V, et al. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol. 1990;44:245-251. (Pubitemid 20269902)
46. Nordlinger B, Parc R, Delva E, et al. Hepatic resection for colorectal liver metastases. Ann Surg. 1987;205:256-263.
47. Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet. 1986;162:109-113. (Pubitemid 16135359)
48. Griffith KD, Sugarbaker PH, Chang AE. Repeat hepatic resections for colorectal metastases. Br J Surg. 1990;77:230-233.
49. Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg. 1988;155:378-382.
50. Lange JF, Leese T, Castaing D, et al. Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet. 1989;169:119-126. (Pubitemid 19200142)
51. Pastana C, Reitmeier RJ, Moertel CG, et al. The natural history of carcinoma of the colon and rectum. Am J Surg. 1964;108:826-829.
52. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancers. Arch Surg. 1976;111:330-334.
53. Scheele J, Strangl R, Altendor-Hofman A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on natural history. Br J Surg. 1990;77:1241-1246.
54. Rivoire M, De CF, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95:2283-2292.
55. Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10:1059-1069.
56. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
57. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976-4982.
58. Park R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753-761.
59. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
60. Kemeny MM, Adak S, Lipsitz S, et al. Results of the intergroup [Eastern Coorperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal metastases. Proc Am Soc Clin Oncol. 1999;18:264 (abstract).
61. Bozzetti F, Bignami P, Montalto F, et al. Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg. 1992;79:146-148.
62. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-520.
63. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-657.
64. Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intraarterial chemotherapy. Surgery. 2002;131:433-442. (Pubitemid 34289734)
65. Kemeny NE, Huitzil Melendez FD, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465-3471.
66. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243-9249.
67. Tabernero J, Van CE, Az-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225-5232.
68. Fong Y, Bentrem DJ. CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg. 2006;243:8-9.
69. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2009;16:137-144.
70. Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293-299.
71. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713-8716.
72. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97: 1035-1039.
73. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst. 1998;89:790-795.
74. Schrag D. The price tag on progress- chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
75. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer. Crit Rev Oncol Hematol. 1999;32:125-131.
76. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395-1403.
77. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039-2048.